TickerGuard
Buy Day today: Neutral (46) Mixed market breadth · no major macro event
NRXP

NRX Pharmaceuticals Inc

Healthcare · Biotechnology

2.30$ -14.7% vs. previous close Closing price · As of: Oct 30, 2026

Ownership

Ownership Structure

Who owns NRX Pharmaceuticals Inc (NRXP)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 86.4% of the shares are freely tradable; institutional investors hold 17.5%.

Institutional ownership ?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings. 17.5%
Insiders ?Share of the stock held by the executives, founders and major shareholders of the company itself. 7.6%
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 86.4%
Short % of float ?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices. 23.6%
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 43Mio.

Largest Shareholders

Institutions

Institutions NRXP
Name Stake (%) Shares Change (%) Date
B Group, Inc 9.45 4,091,767 +36.4 06/30/2026
Vanguard Capital Management, LLC 3.74 1,618,159 +39.5 06/30/2026
Ameriprise Financial Inc 2.15 928,728 +0.0 06/30/2026
Balyasny Asset Management LLC 2.06 893,864 +0.0 06/30/2026
Citadel Advisors Llc 1.57 680,043 +0.0 06/30/2026
AdvisorShares Investments, LLC 1.52 659,018 +56.7 06/30/2026
Commonwealth Equity Services, LLC 1.05 454,418 +14.3 06/30/2026
UBS Group AG 0.98 423,115 +1,577.2 06/30/2026

Funds

Funds NRXP
Name Stake (%) Shares Change (%) Date
Vanguard MStar Total Stk Mkt Idx Invest 2.93 1,267,102 +0.0 09/30/2026
AdvisorShares Psychedelics ETF 1.86 805,066 +0.0 09/30/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Data as of: October 30, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?